Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Drugpatentwatch crizotinib?
Pramlintide approval date?
Atorvastatin side effects heart palpitations?
Bortezomib market france?
Somatuline depot patent expiry date?

Can jardiance be safely used in patients with chronic kidney disease?

See the DrugPatentWatch profile for jardiance

Short answer:
Yes—empagliflozin (Jardiance) can be used safely in many people with chronic kidney disease (CKD), but only down to a certain kidney‑function threshold and with close monitoring.

1. What the drug is and why it matters for CKD

Drug Class Key benefits in CKD
Empagliflozin (Jardiance) SGLT2 inhibitor • Lowers blood glucose (for diabetics)
• Slows CKD progression (both diabetic and non‑diabetic)
• Reduces risk of end‑stage kidney disease (ESKD)
• Improves cardiovascular outcomes

Recent trials (EMPA‑REG OUTCOME, EMPA‑Hepatology, EMPA‑Kidney) and the 2023 FDA label update now recognize empagliflozin as a kidney‑protective therapy for CKD stages 3‑4 regardless of diabetes status.

2. When it is not recommended

Population Why it’s off‑label
eGFR < 30 mL/min/1.73 m² (type 2 diabetes) The glucose‑lowering effect is minimal, and the drug offers no proven benefit.
eGFR < 20 mL/min/1.73 m² (CKD with or without diabetes) Insufficient data; the drug may be ineffective and could increase adverse events.

Bottom line: If your kidney function (estimated glomerular filtration rate, eGFR) is below 20 mL/min/1.73 m², Jardiance should not be started.

3. Starting the medication (typical protocol)

Step Action Why it matters
Baseline labs eGFR, electrolytes (Na, K, Mg), serum creatinine, urinalysis Establish starting kidney function and rule out other problems.
Dose 10 mg once daily (or 5 mg if eGFR 45–60 mL/min/1.73 m² and you’re cautious). 10 mg is the FDA‑approved dose for CKD; no dose adjustment for eGFR > 20.
First‑dose monitoring Recheck eGFR 1–2 weeks after initiation (or sooner if symptoms). Detect any early decline in kidney function.
Ongoing monitoring eGFR & creatinine at 1 month, then every 3 months. Track long‑term kidney safety and benefit.
Hydration Encourage adequate fluid intake, especially if on diuretics. Prevent volume depletion and acute kidney injury.
Adverse‑event vigilance Watch for genital yeast infections, urinary tract infections, hypotension, and ketoacidosis. Early identification improves safety.
Drug interactions Avoid simultaneous use of ACE inhibitors/ARBs only if you’re on high doses of diuretics that could cause hypotension. Reduce risk of acute kidney injury or hyperkalemia.

4. How it works in CKD

  • SGLT2 inhibition reduces glucose reabsorption in the proximal tubule, leading to mild osmotic diuresis and decreased intraglomerular pressure.
  • The nephroprotective effect is independent of glucose lowering: it reduces hyperfiltration, lowers albuminuria, and preserves nephron integrity.
  • In non‑diabetic CKD, empagliflozin has been shown in the EMPA‑Kidney trial to reduce the composite endpoint of ESKD, doubling of serum creatinine, or death from kidney disease by about 30% compared to placebo.

5. Special considerations

Scenario Recommendation
Diabetic CKD with eGFR 30–45 Continue empagliflozin; monitor eGFR closely.
Diabetic CKD with eGFR 20–30 You can keep the drug if you’re seeing benefit, but the label advises discontinuation when eGFR falls below 30.
Non‑diabetic CKD with eGFR 20–45 Empagliflozin is now approved; monitor as above.
Severe CKD (stage 4 or 5) with eGFR < 20 Not recommended; no proven benefit.
Pregnancy Not recommended.
Concurrent nephrotoxic drugs (e.g., aminoglycosides, NSAIDs) Use cautiously; consider dose adjustments or alternative agents.

6. Practical tips for patients

  1. Stay hydrated. Drink 1.5–2 L of fluid daily unless your doctor says otherwise.
  2. Notice infections early. Report genital itching, discharge, or urinary symptoms promptly.
  3. Check your blood pressure. If you’re on antihypertensives, keep a log; sudden drops may signal volume loss.
  4. Keep appointments. Your nephrologist or diabetes team should review your labs every 3 months.
  5. Do not stop the medication abruptly without consulting your clinician; a taper or switch may be needed if eGFR declines.

7. Bottom line for you

  • Jardiance can be a useful, kidney‑protective drug in CKD stages 3–4 (eGFR ≥ 20 mL/min/1.73 m²).
  • It is not indicated once eGFR falls below 20 mL/min/1.73 m² or if the patient has severe CKD (stage 5) or is pregnant.
  • Close monitoring of kidney function, electrolytes, and potential side effects is essential.
  • Discuss with your nephrologist or endocrinologist before starting or stopping the medication; they’ll tailor the plan to your exact eGFR, comorbidities, and other medications.

Quick reference table

eGFR CKD stage Jardiance use Notes
≥ 60 1 Yes (if diabetic or CKD


Other Questions About Jardiance :

when is jardiance going generic Jardiance and renal function? When will jardiance generic be available? Best price for jardiance 10 mg? Aifa jardiance? Does jardiance lower creatinine levels? When does jardiance become generic?